The Insect Peptide Coprisin Prevents Clostridium difficile-Mediated Acute Inflammation and Mucosal Damage through Selective Antimicrobial Activity
Authors:
- 1 October 2011
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (10) , 4850-4857
Abstract
Clostridium difficile -associated diarrhea and pseudomembranous colitis are typically treated with vancomycin or metronidazole, but recent increases in relapse incidence and the emergence of drug-resistant strains of C. difficile indicate the need for new antibiotics. We previously isolated coprisin, an antibacterial peptide from Copris tripartitus , a Korean dung beetle, and identified a nine-amino-acid peptide in the α-helical region of it (LLCIALRKK) that had antimicrobial activity (J.-S. Hwang et al., Int. J. Pept., 2009, doi:10.1155/2009/136284). Here, we examined whether treatment with a coprisin analogue (a disulfide dimer of the nine peptides) prevented inflammation and mucosal damage in a mouse model of acute gut inflammation established by administration of antibiotics followed by C. difficile infection. In this model, coprisin treatment significantly ameliorated body weight decreases, improved the survival rate, and decreased mucosal damage and proinflammatory cytokine production. In contrast, the coprisin analogue had no apparent antibiotic activity against commensal bacteria, including Lactobacillus and Bifidobacterium , which are known to inhibit the colonization of C. difficile . The exposure of C. difficile to the coprisin analogue caused a marked increase in nuclear propidium iodide (PI) staining, indicating membrane damage; the staining levels were similar to those seen with bacteria treated with a positive control for membrane disruption (EDTA). In contrast, coprisin analogue treatment did not trigger increases in the nuclear PI staining of Bifidobacterium thermophilum . This observation suggests that the antibiotic activity of the coprisin analogue may occur through specific membrane disruption of C. difficile . Thus, these results indicate that the coprisin analogue may prove useful as a therapeutic agent for C. difficile infection-associated inflammatory diarrhea and pseudomembranous colitis.Keywords
This publication has 51 references indexed in Scilit:
- Generic Vancomycin Products FailIn Vivodespite Being Pharmaceutical Equivalents of the InnovatorAntimicrobial Agents and Chemotherapy, 2010
- The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial PeptidePLOS ONE, 2010
- Isolation and Characterization of a Defensin-Like Peptide (Coprisin) from the Dung Beetle,Copris tripartitusInternational Journal of Peptides, 2009
- Therapeutic Potential of Two Probiotics in Inflammatory Bowel Disease as observed in the Trinitrobenzene Sulfonic Acid Model of ColitisDiseases of the Colon & Rectum, 2008
- Metronidazole Resistance in Clostridium difficile Is HeterogeneousJournal of Clinical Microbiology, 2008
- Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile -Associated Diarrhea and Prevention of Disease Recurrence in HamstersAntimicrobial Agents and Chemotherapy, 2008
- Response of the Microaerophilic Bifidobacterium Species, B. boum and B. thermophilum , to OxygenApplied and Environmental Microbiology, 2006
- Clostridium difficile Toxin A Regulates Inducible Cyclooxygenase-2 and Prostaglandin E2 Synthesis in Colonocytes via Reactive Oxygen Species and Activation of p38 MAPKJournal of Biological Chemistry, 2005
- Susceptibility of Nontypeable Haemophilus influenzae to Human β-Defensins Is Influenced by Lipooligosaccharide AcylationInfection and Immunity, 2002
- Clostridium difficileGastroenterology Clinics of North America, 2001